Zhengkai Liao
Overview
Explore the profile of Zhengkai Liao including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
20
Citations
150
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Fang R, Yan L, Xu S, Xu Y, Gan T, Gong J, et al.
Front Immunol
. 2024 Sep;
15:1439877.
PMID: 39253074
Background: The advent of immunotherapy has changed the landscape of SCLC treatment, although the identification of reliable prognostic biomarkers remains a formidable challenge. Our objective was to investigate the prognostic...
2.
Xia L, Shi W, Cai Y, Liao Z, Huang Z, Qiu H, et al.
Int J Surg
. 2024 Jun;
111(1):70-79.
PMID: 38920327
Background: For stage T1b-2N0-1 esophageal cancer, the impact of neoadjuvant therapy plus surgery (NS), surgery alone (SA), and surgery plus adjuvant therapy (ST) on cancer-specific survival (CSS) and overall survival...
3.
Zhang J, Li Y, Dai W, Tang F, Wang L, Wang Z, et al.
Cancer Immunol Immunother
. 2024 Mar;
73(4):71.
PMID: 38430394
Background: Due to individual differences in tumors and immune systems, the response rate to immunotherapy is low in lung adenocarcinoma (LUAD) patients. Combinations with other therapeutic strategies improve the efficacy...
4.
Fang R, Xu S, Gong J, Liao Z
Onco Targets Ther
. 2024 Jan;
17:27-31.
PMID: 38283732
Aim: BRAF is a pivotal driver gene in cancer development. Based on this, the combination of dabrafenib and trametinib was approved for treating NSCLC patients with BRAF mutations. However, the...
5.
Fang R, Gong J, Liao Z
Front Oncol
. 2023 Aug;
13:1220745.
PMID: 37546400
Background: The pulmonary sarcomatoid carcinoma (PSC) is a rare and aggressive subtype of NSCLC with rapid progression and poor prognosis, and is resistant to conventional chemotherapy. Most PSC cases have...
6.
Fang R, Yan L, Liao Z
Front Oncol
. 2023 May;
13:1123567.
PMID: 37205195
Cancer-associated cachexia (CAC) is a major characteristic of advanced cancer, associates with almost all types of cancer. Recent studies have found that lipopenia is an important feature of CAC, and...
7.
Yang R, Gong J, Liao Z, Yu J, Zhang J, Xie C
Transl Cancer Res
. 2022 Aug;
11(7):2194-2204.
PMID: 35966291
Background: The role of postoperative radiotherapy (PORT) in resected stage IIIa-N2 non-small cell lung cancer (NSCLC) patients who have received adjuvant chemotherapy remains controversial. This study aimed to explore the...
8.
Chen C, Liao Z, Chmura S, Weichselbaum R
Adv Radiat Oncol
. 2020 Aug;
5(4):637-639.
PMID: 32775773
No abstract available.
9.
Ouyang W, Yu J, Huang Z, Chen G, Liu Y, Liao Z, et al.
J Cancer
. 2020 Mar;
11(8):2060-2067.
PMID: 32127933
: It is still controversial to employ osimertinib as the first-line therapy for EGFR-mutated non-small cell lung cancer (NSCLC) patients in practice. The aim of the current study was to...
10.
Yu J, Ouyang W, Li Y, Hu J, Xu Y, Wei Y, et al.
Cancer Med
. 2018 Dec;
8(1):21-27.
PMID: 30561117
To determine the value of radiotherapy in addition to esophagectomy for stage II and III TESCC. We searched the Surveillance, Epidemiology, and End Results (SEER) database for all cases of...